Drug application
EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, TENOFOVIR ALAFENAMIDE FUMARATE)
Drugs@FDA ANDA 214095 · APOTEX
Key facts
| Drug name | EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE |
|---|---|
| Active ingredients | EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, TENOFOVIR ALAFENAMIDE FUMARATE |
| Application type | ANDA |
| Application number | 214095 |
| Company | APOTEX |
| Dosage forms | TABLET, ORAL |
| Strength | 200MG;EQ 25MG BASE;EQ 25MG BASE |
| Marketing status | Discontinued |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Jan 30, 2026 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: